BRPI1012638A2 - métodos e intermediários para preparar agentes farmacêuticos - Google Patents

métodos e intermediários para preparar agentes farmacêuticos

Info

Publication number
BRPI1012638A2
BRPI1012638A2 BRPI1012638A BRPI1012638A BRPI1012638A2 BR PI1012638 A2 BRPI1012638 A2 BR PI1012638A2 BR PI1012638 A BRPI1012638 A BR PI1012638A BR PI1012638 A BRPI1012638 A BR PI1012638A BR PI1012638 A2 BRPI1012638 A2 BR PI1012638A2
Authority
BR
Brazil
Prior art keywords
intermediates
methods
pharmaceutical agents
preparing pharmaceutical
preparing
Prior art date
Application number
BRPI1012638A
Other languages
English (en)
Inventor
Aaron Cullen
Doug Cordeau
Duong Tran
Eric Dowdy
Kenneth Kent
Leah Easton
Richard Polniaszek
Richard Yu
Steven Pfeiffer
Zhongxin Zhou
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012638(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BRPI1012638A2 publication Critical patent/BRPI1012638A2/pt
Publication of BRPI1012638B1 publication Critical patent/BRPI1012638B1/pt
Publication of BRPI1012638B8 publication Critical patent/BRPI1012638B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/70Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/34Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04Diamides of sulfuric acids
    • C07C307/06Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
BRPI1012638A 2009-04-03 2010-04-01 métodos e intermediários para preparar agentes farmacêuticos BRPI1012638B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16649809P 2009-04-03 2009-04-03
US61/166,498 2009-04-03
PCT/US2010/029633 WO2010115000A2 (en) 2009-04-03 2010-04-01 Methods and intermediates for preparing pharmaceutical agents

Publications (3)

Publication Number Publication Date
BRPI1012638A2 true BRPI1012638A2 (pt) 2016-04-05
BRPI1012638B1 BRPI1012638B1 (pt) 2021-04-20
BRPI1012638B8 BRPI1012638B8 (pt) 2021-05-25

Family

ID=42634770

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012638A BRPI1012638B8 (pt) 2009-04-03 2010-04-01 métodos e intermediários para preparar agentes farmacêuticos

Country Status (27)

Country Link
US (4) US8497396B2 (pt)
EP (2) EP3009434A1 (pt)
JP (8) JP5612662B2 (pt)
KR (3) KR101874557B1 (pt)
CN (4) CN107382997B (pt)
AP (1) AP2887A (pt)
AR (1) AR076027A1 (pt)
AU (1) AU2010232559B2 (pt)
BR (1) BRPI1012638B8 (pt)
CA (4) CA2754698C (pt)
CL (1) CL2011002370A1 (pt)
CO (1) CO6400216A2 (pt)
EA (2) EA022739B1 (pt)
EC (1) ECSP11011391A (pt)
ES (1) ES2548252T3 (pt)
HK (4) HK1166976A1 (pt)
IL (4) IL215399A (pt)
MX (2) MX338731B (pt)
NZ (4) NZ617773A (pt)
PE (1) PE20120617A1 (pt)
PT (1) PT2414325E (pt)
SG (2) SG174585A1 (pt)
TW (2) TWI464165B (pt)
UA (1) UA108738C2 (pt)
UY (1) UY32535A (pt)
WO (1) WO2010115000A2 (pt)
ZA (1) ZA201107430B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
JP2012140390A (ja) * 2011-01-06 2012-07-26 Sumitomo Chemical Co Ltd α−アミノ−γ−ブチロラクトンの製造方法
WO2012151165A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
CN104093702A (zh) 2012-02-03 2014-10-08 吉里德科学公司 用于制备药物试剂的方法和中间体
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014047849A1 (zh) * 2012-09-27 2014-04-03 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
JP2016504364A (ja) * 2012-12-26 2016-02-12 アッシア・ケミカル・インダストリーズ・リミテッド コビシスタット塩
CN104370777A (zh) * 2013-08-13 2015-02-25 上海迪赛诺化学制药有限公司 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用
EP3073993A1 (en) * 2013-11-29 2016-10-05 Mylan Laboratories Ltd. Amorphous cobicistat solid dispersion
WO2015083066A1 (en) 2013-12-03 2015-06-11 Mylan Laboratories Ltd. Preparation of cobicistat intermediates
CN104193643B (zh) * 2014-09-12 2016-02-10 宁波九胜创新医药科技有限公司 用于合成抗艾滋病药物增强剂cobicistat的中间体
CN104447472A (zh) * 2014-11-06 2015-03-25 江苏森萱医药化工股份有限公司 D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法
CN104557565B (zh) * 2015-01-08 2016-07-06 浙江工业大学 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法
US10454867B2 (en) * 2015-02-09 2019-10-22 Airwatch Llc Enhanced e-mail delivery to mobile devices
US10351556B2 (en) 2015-02-18 2019-07-16 Msn Laboratories Private Limited Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate
CN107674039A (zh) * 2016-08-01 2018-02-09 上海朴颐化学科技有限公司 一种可比西他中间体的制备方法
EP3518935A1 (en) 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110878071A (zh) * 2019-11-21 2020-03-13 华南农业大学 一种α-氨基-γ-丁内酯及其盐的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100815412B1 (ko) * 1999-06-04 2008-03-20 아보트 러보러터리즈 개선된 약제학적 제형
US20030153771A1 (en) 2001-09-27 2003-08-14 Kolb Hartmuth C. Large scale synthesis of optically pure aziridines
WO2003106445A1 (en) * 2002-06-12 2003-12-24 Qsi Pharma A/S Compounds and methods for controlling bacterial virulence
CN1989232A (zh) * 2004-07-23 2007-06-27 宝洁公司 用于改善低温下油脂清洁和淀粉污垢清洁效果的液体洗涤剂组合物
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
CA2653374A1 (en) * 2006-07-07 2008-01-24 Manoj C. Desai Modulators of pharmacokinetic properties of therapeutics
ES2779826T3 (es) * 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
KR20100040896A (ko) * 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
JP5629585B2 (ja) * 2008-01-04 2014-11-19 ギリアード サイエンシーズ, インコーポレイテッド シトクロムp450のインヒビター
JP5722213B2 (ja) 2008-05-02 2015-05-20 ギリアード サイエンシーズ, インコーポレイテッド 医薬薬剤の加工性を改良するための固体担体粒子の使用
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Also Published As

Publication number Publication date
JP2016128476A (ja) 2016-07-14
NZ708978A (en) 2017-01-27
US8853210B2 (en) 2014-10-07
IL237642A (en) 2017-01-31
AP2887A (en) 2014-05-31
JP2023002679A (ja) 2023-01-10
AU2010232559A8 (en) 2011-11-10
CA3008903A1 (en) 2010-10-07
AP2011005864A0 (en) 2011-10-31
US20100256366A1 (en) 2010-10-07
JP5612662B2 (ja) 2014-10-22
WO2010115000A3 (en) 2011-09-22
JP2014193897A (ja) 2014-10-09
CA2925137C (en) 2018-07-31
BRPI1012638B8 (pt) 2021-05-25
CN111217808A (zh) 2020-06-02
CA2925137A1 (en) 2010-10-07
SG10201404926UA (en) 2015-02-27
JP6336161B2 (ja) 2018-06-06
IL250068A0 (en) 2017-03-30
WO2010115000A2 (en) 2010-10-07
UY32535A (es) 2010-10-29
IL215399A (en) 2015-11-30
US8497396B2 (en) 2013-07-30
IL237643A (en) 2017-01-31
MX338731B (es) 2016-04-28
CN107382997A (zh) 2017-11-24
NZ726536A (en) 2018-04-27
PT2414325E (pt) 2015-10-29
KR20170043672A (ko) 2017-04-21
HK1166976A1 (zh) 2012-11-16
KR20180077324A (ko) 2018-07-06
BRPI1012638B1 (pt) 2021-04-20
CA3008903C (en) 2021-06-08
CA2754698C (en) 2016-06-07
NZ617773A (en) 2016-02-26
PE20120617A1 (es) 2012-05-26
CA3083433C (en) 2022-08-09
TW201518283A (zh) 2015-05-16
US9115100B2 (en) 2015-08-25
EA022739B1 (ru) 2016-02-29
IL215399A0 (en) 2011-12-29
AU2010232559A1 (en) 2011-10-06
CA2754698A1 (en) 2010-10-07
KR20120006035A (ko) 2012-01-17
JP6491706B2 (ja) 2019-03-27
EP2414325B1 (en) 2015-08-26
JP2012522797A (ja) 2012-09-27
TW201100412A (en) 2011-01-01
TWI464165B (zh) 2014-12-11
JP2018008983A (ja) 2018-01-18
NZ594864A (en) 2014-03-28
ZA201107430B (en) 2012-12-27
JP2020189861A (ja) 2020-11-26
CA3083433A1 (en) 2010-10-07
AU2010232559B2 (en) 2015-06-18
HK1214265A1 (zh) 2016-07-22
MX2011010397A (es) 2011-10-24
US20150005493A1 (en) 2015-01-01
CN104876888A (zh) 2015-09-02
JP2018162274A (ja) 2018-10-18
CN104876888B (zh) 2018-06-15
KR101728375B1 (ko) 2017-04-19
ECSP11011391A (es) 2012-03-30
EP2414325A2 (en) 2012-02-08
KR101874557B1 (ko) 2018-07-04
IL237643A0 (en) 2015-04-30
SG174585A1 (en) 2011-10-28
US9428473B2 (en) 2016-08-30
CN107382997B (zh) 2021-02-26
CN102438982A (zh) 2012-05-02
ES2548252T3 (es) 2015-10-15
EP3009434A1 (en) 2016-04-20
HK1245785A1 (zh) 2018-08-31
CN102438982B (zh) 2015-05-06
CL2011002370A1 (es) 2012-05-25
US20140088304A1 (en) 2014-03-27
JP5986599B2 (ja) 2016-09-06
IL237642A0 (en) 2015-04-30
JP6180561B2 (ja) 2017-08-16
UA108738C2 (uk) 2015-06-10
JP2017122107A (ja) 2017-07-13
CO6400216A2 (es) 2012-03-15
AR076027A1 (es) 2011-05-11
EA201590979A1 (ru) 2016-02-29
HK1223912A1 (zh) 2017-08-11
US20160002186A1 (en) 2016-01-07
EA201190179A1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
BR112012004807A2 (pt) vacina para pcsk9
BRPI1012148A2 (pt) método e equipamento para preparar dentadura
BR112012025697A2 (pt) "dispositivo e método para conjunto estrutural"
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
BRPI1008598A2 (pt) composição farmacêutica para inalação
BR112012002335A2 (pt) pigmento composto e método para preparação do mesmo
UY33094A (es) Procedimiento para la preparacion de dronedarona
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BRPI1006861A2 (pt) métodos para isolar bactérias
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
BRPI1009191A2 (pt) dispositivo para administração intranasal
BRPI0922653A2 (pt) preparação farmacêutica
BR112013006131A2 (pt) inibidores de notum pectinacetilesterase e métodos para sua utilização
BR112013015979A2 (pt) tampão de fratura modular e método para a construção do mesmo
BR112013008074A2 (pt) combinações farmacêuticas
BRPI1015535A2 (pt) coquilha para lingotamento contínuo
BRPI1010642A2 (pt) tecnologias de plataforma para doenças ocorrendo espontaneamente
BRPI0908497A2 (pt) métodos e composições para um rendimento aumentado
BR112012000579A2 (pt) método para conclusão do poço
BRPI0918190A2 (pt) metodo para administrar agentes farmaceuticos
ES1070148Y (es) Macolla para barrotes mejorada
ES1074944Y (es) Envase monodosis para dentifricos y similares
ES1071124Y (es) Parapente para aeromodelismo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF